Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'